Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Recarbrio in ECMO Patients
NCT04493151Phase 1Completed
- Sponsor
- Joseph L. Kuti
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imipenem + cilastatin + relebactam in sepsis, sponsored by Joseph L. Kuti. Primary endpoints: Imipenem Clearance at 6 hours and Relebactam Clearance at 6 hours. Started Jan 2021; status: completed.
02
Drugs
imipenem + cilastatin + relebactam
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT04493151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493151.